Beam Therapeutics Inc.Beam Therapeutics Inc.Beam Therapeutics Inc.

Beam Therapeutics Inc.

No trades
See on Supercharts

Key facts today


RBC Capital Markets has lowered its price target for Beam Therapeutics from $26 to $20, while keeping a 'Sector Perform' rating, reflecting a level of speculative risk associated with the stock.
Analyze the impactAnalyze the impact

See all ideas 

Displays a symbol's price movements over previous years to identify recurring trends.